(MENAFN - Comserve) Shibuya-ku, Tokyo, Japan, Japan, Apr 26, 2021, 05:35 /Comserve / Competitive Analysis: Roche, Pfizer, Abbvie, Johnson, Sanofi, Merck, Novartis, Gilead, GSK, Amgen
Dalbavancin Market By Product Type (Intravenous Therapy, Oral Type) and Application (Skin Infection, Soft Tissue Infection, Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Dalbavancin Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Dalbavancin is a second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients suffering with methicillin-resistant Staphylococcus aureus (MRSA).